Drugs / 426c.Mod.Core-C4b
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT06613789 | Mar → Jun 2027 expected | HIV infectious disease | HIV Vaccine Trials Network | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT06006546 | Jan 2024 → Oct 2026 expected | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Active not recruiting | No outcome recorded |
| Phase 1 | NCT05471076 | Aug 2022 → Dec 2025 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT06796686 Comparator | Mar 2025 → Jan 2027 expected | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 426c.Mod.Core-C4b | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06613789 ↗ |
| Modality | Protein / enzyme biologic | “recombinant Env immunogen” NCT05471076 ↗ |
| Route | Intramuscular | “into the deltoid muscle” NCT05471076 ↗ |